,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSEUA4'}, 'Id': 'a0P2P000005KWSEUA4', 'Event_Date__c': '2018-06-08', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArTmQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSFUA4'}, 'Id': 'a0P2P000005KWSFUA4', 'Event_Date__c': '2018-09-03', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArWIQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSGUA4'}, 'Id': 'a0P2P000005KWSGUA4', 'Event_Date__c': '2018-09-03', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArWLQA0'}, 'change': None}]",Jun 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'Applications received from Max Health and Te Arai BioFarma following call for applications for medicines for rare disorders. To be considered at November 2018 Rare Disorders Subcommittee meeting', 'fs': 'Applications received from Max Health and Te Arai BioFarma following call for applications for medicines for rare disorders. To be considered at November 2018 Rare Disorders Subcommittee meeting', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSHUA4'}, 'Id': 'a0P2P000005KWSHUA4', 'Event_Date__c': '2018-09-25', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'Applications received from Max Health and Te Arai BioFarma following call for applications for medicines for rare disorders. To be considered at November 2018 Rare Disorders Subcommittee meeting', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArXwQAK'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that carglumic acid be funded with a high priority for the treatment of hyperammonaemia due to carbamoyl phosphate synthetase 1 (CPS1) or N-acetylglutamate synthase (NAGS) deficiency based on high health need, a lack of treatment options, and moderate evidence of benefit, subject to Special Authority criteria', 'fs': 'The Subcommittee recommended that carglumic acid be funded with a high priority for the treatment of hyperammonaemia due to carbamoyl phosphate synthetase 1 (CPS1) or N-acetylglutamate synthase (NAGS) deficiency based on high health need, a lack of treatment options, and moderate evidence of benefit, subject to Special Authority criteria', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2018', 'fs': 'Nov 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'fs': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSIUA4'}, 'Id': 'a0P2P000005KWSIUA4', 'Event_Date__c': '2018-11-05', 'Event_Description__c': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee recommended that carglumic acid be funded with a high priority for the treatment of hyperammonaemia due to carbamoyl phosphate synthetase 1 (CPS1) or N-acetylglutamate synthase (NAGS) deficiency based on high health need, a lack of treatment options, and moderate evidence of benefit, subject to Special Authority criteria', 'Formatted_Date__c': 'Nov 2018', 'Status_History__c': 'a132P000000ArZGQA0'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that carglumic acid be funded with a medium priority for the short-term treatment of hyperammonaemia during an acute decompensation episode due to organic acidaemias, based on high health need and moderate evidence of benefit, subject to Special Authority criteria.', 'fs': 'The Subcommittee recommended that carglumic acid be funded with a medium priority for the short-term treatment of hyperammonaemia during an acute decompensation episode due to organic acidaemias, based on high health need and moderate evidence of benefit, subject to Special Authority criteria.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2018', 'fs': 'Nov 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'fs': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSJUA4'}, 'Id': 'a0P2P000005KWSJUA4', 'Event_Date__c': '2018-11-05', 'Event_Description__c': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'Outcome__c': 'Medium', 'Summary__c': 'The Subcommittee recommended that carglumic acid be funded with a medium priority for the short-term treatment of hyperammonaemia during an acute decompensation episode due to organic acidaemias, based on high health need and moderate evidence of benefit, subject to Special Authority criteria.', 'Formatted_Date__c': 'Nov 2018', 'Status_History__c': 'a132P000000ArZIQA0'}, 'change': None}, {'Summary': {'s': 'The Subcommittee minutes will be considered at the February 2019 PTAC meeting.', 'fs': 'The Subcommittee minutes will be considered at the February 2019 PTAC meeting.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSKUA4'}, 'Id': 'a0P2P000005KWSKUA4', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'The Subcommittee minutes will be considered at the February 2019 PTAC meeting.', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArbcQAC'}, 'change': None}, {'Summary': {'s': 'PTAC accepted the positive recommendation of the Rare Disorders Subcommittee that this medicine be funded with a high priority for the treatment of hyperammonaemia due to carbamoyl phosphate synthetase 1 (CPS1) or N-acetylglutamate synthase (NAGS) deficiency.  PTAC also accepted the positive recommendation of the Rare Disorders Subcommittee that this medicine be funded with a medium priority for the short-term treatment of hyperammonaemia during an acute decompensation episode due to organic acidaemias.', 'fs': 'PTAC accepted the positive recommendation of the Rare Disorders Subcommittee that this medicine be funded with a high priority for the treatment of hyperammonaemia due to carbamoyl phosphate synthetase 1 (CPS1) or N-acetylglutamate synthase (NAGS) deficiency.  PTAC also accepted the positive recommendation of the Rare Disorders Subcommittee that this medicine be funded with a medium priority for the short-term treatment of hyperammonaemia during an acute decompensation episode due to organic acidaemias.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSLUA4'}, 'Id': 'a0P2P000005KWSLUA4', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'PTAC accepted the positive recommendation of the Rare Disorders Subcommittee that this medicine be funded with a high priority for the treatment of hyperammonaemia due to carbamoyl phosphate synthetase 1 (CPS1) or N-acetylglutamate synthase (NAGS) deficiency.  PTAC also accepted the positive recommendation of the Rare Disorders Subcommittee that this medicine be funded with a medium priority for the short-term treatment of hyperammonaemia during an acute decompensation episode due to organic acidaemias.', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArbjQAC'}, 'change': None}]",Sep 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,,,False,False
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2019', 'fs': 'Apr 2019', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005KWSMUA4'}, 'Id': 'a0P2P000005KWSMUA4', 'Event_Date__c': '2019-04-16', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Apr 2019', 'Status_History__c': 'a132P000000AreSQAS'}, 'change': None}]",Apr 2019,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
